IBRANCE® (palbociclib)|P-REALITY X overview| PfizerPro Ireland

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

Clinical efficacy & safety

PALOMA-2

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

PALOMA-2 summary

PALOMA-3

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

Safety

Safety overview

Pooled laboratory abnormalities

PALOMA-2 AEs

PALOMA-3 AEs

Selected safety features

IBRANCE long-term safety

GI and liver toxicities

Effect of IBRANCE on QTc interval

Elderly patients

Visceral disease patients

Dose reduction effect on efficacy

RW evidence

Value of RWE

What is real-world evidence?

What is the value of RWE?

P-REALITY and P-REALITY X

P-REALITY Overview

P-REALITY OS and rwPFS

P-REALITY X Overview

P-REALITY X OS and rwPFS

IRIS

IRIS Overview

IRIS PFS and OS

POLARIS

POLARIS Overview

POLARIS Patient-Reported Outcomes

MADELINE

MADELINE Overview

MADELINE Patient Characteristics

MADELINE Patient-Reported Outcomes

PalomAGE

PalomAGE Overview

RWE in Older Patients with mBC

Patient-reported outcomes

PALOMA-2: FACT-B scores

PALOMA-3: EORTC QLQ-C30 scores

PALOMA-3: Time to deterioration in pain symptoms

Dosing

Recommended dosing schedule

Recommended dose modifications for AEs

Monitoring

One scheduled monitoring provision

Resources

Materials

P-REALITY X overview

P-REALITY X (Palbociclib REAL-world 1^st-line ComparaTive Effectiveness Study eXtended) is a comparative effectiveness study of 1^st-line IBRANCE in combination with AI vs AI alone¹

P-REALITY X study design¹

OS was defined as the number of months from start of study treatment until death.

rwPFS was defined as the number of months from the start of study treatment to the date of the first documentation of real-world progressive disease or death, whichever occurred first.

A total of 2888 patients received IBRANCE in combination with AI or AI alone in the 1^st-line setting¹

sIPTW was the the primary analysis performed to balance baseline demographic and clinical characteristics, and to adjust for differences in observed potential confounders between the two groups.¹ 1:1 PSM was conducted as a sensitivity analysis.¹

The study included a heterogeneous population in terms of age, performance status and disease site¹

Select baseline patient characteristics after sIPTW adjustment (n=2709)^*1

Adapted from Rugo H, et al. 2022.²
Median follow-up (IQR) was 23.9 (12.8–38.0) months with IBRANCE + AI and 24.5 (12.0–42.9) months with AI alone. Patient characteristics were generally well balanced across groups after sIPTW and PSM adjustment.

sIPTW was applied to balance patient demographic and baseline clinical characteristics. This approach was used as the primary analysis.

Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.

Bone-only disease was defined as metastatic disease in the bone only.

34.0% of patients after sIPTW presented with de novo mBC at baseline¹
30.3% of patients after sIPTW had an ECOG performance status score of 0; 22.9% a score of 1 and 15.5% a score of 2, 3 or 4¹

Observational retrospective analyses are designed to evaluate associations among variables and cannot establish causality. Observational retrospective analyses are not intended for direct comparison with clinical trials.^2,3

Explore More

P-REALITY X OS and rwPFS

Explore more

P-REALITY overview

Explore more

AI = aromatase inhibitor; ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; mBC = metastatic breast cancer; N/n = number of patients; PSM = propensity score matching; sIPTW = stabilized inverse probability treatment weighting.

References:

Rugo HS, et al. NPJ Breast Cancer. 2022;8(1):114.

Gerstein HC, et al. Lancet. 2019;393(10168):210-211.

Corrigan-Curay J, et al. JAMA. 2018;320(9):867-868.

P-REALITY and P-REALITY X

IBRANCE Summary of Product Characteristics

Product Characteristics

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0649. August 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

PP-UNP-IRL-0733. March 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024